Use of azithromycin (Sumamed) in therapeutical practice


Cite item

Full Text

Abstract

We consider the antibiotic of macrolides - azithromycin (Sumamed) as one of the advanced drug for treatment of respiratory tract infections. Its advantage is a wide range of actions, including almost all the major pathogens of respiratory tract infections, including intracellular parasites. Azithromycin have activity against pneumococci, streptococci, Legionella, mycoplasma and chlamydia similar to other macrolides, but exceeds them by the activity against other pathogens of respiratory tract infections. Peculiarities of the azithromycin pharmacokinetics determine its advantages, in particular the prolonged half-life, so that the drug can be applied once a day by short courses - for 3-5 days. In numerous clinical studies high efficiency and good tolerance of azithromycin in comparison with other antibiotics were demonstrated, including in the treatment of respiratory tract infections in children, elderly patients.

About the authors

S B Erofeeva

S B Erofeeva

References

  1. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108(Suppl.):43-52.
  2. Fine M. Aetiology and incidence of community-acquired pneumonia. Infect Dis Clin Pract 1996:5(Suppl. 4):S127-35.
  3. Bartlett JG, Mundy LM. Community-acquired pneumonia. New EnglJ Med 1995,14:1618-24.
  4. Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia for adults. Clin Infect Dis 2000;31:347-82.
  5. Murphy SL. Deaths: final data for 1998. Nat Vital Stat Rep 2000;48:1-106.
  6. Лукьянов С.В. Клиническая фармакология макролидов // Consilium medicum. 2004;6(10):769-73.
  7. Синопалъников A.M., Фесенко О.В. Российские медицинские вести. 1998. № 3. C. 69-74.
  8. Lynch JP. In: Pulmonary Disease Diagnosis and Therapy. Khan M.G., Lunch J.P. eds. 1997;297-374.
  9. Иоников В.Е. Клиническая фармакология и терапия. 1994. № 2. С. 49-52.
  10. Cosentini R, Blasi F, et at. Communityacquired pneumonia: role of atypical organisms, Monaldi Arch Chest Dis 2001;56:527-34.
  11. Gleason PP. The emerging role of atypical pathogens in community-acquired pneumonia. Pharmacotherapy 2002;22(1 Pt2):2-11S.
  12. Guidelines for management of adult communityacquired lower respiratory tract infections. European Study on Community-acquired Pneumonia < ESOCAP) Committee. Cur Resp J 1998;14:986-91.
  13. Leclerq R, Courvalin P. Resistance to macrolides, azalides, and streptogramins. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu H.C., Young L.S., Zinner S.H., Acar J.F. (Eds.). New York, etc., 1995:31-40.
  14. Drew R.H., Gallis H.A. Azithromycin - spectrum of activity, pharmacokinetics and clinical applications. Pharmacotherapy 1992;12:161-173.
  15. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-1 и ПеГАС-II // Клиническая микробиология и антимикробная химиотерапия. 2006. № 8. С. 33-47.
  16. Fass RJ. Erythromycin, clarithromycin and azithromycin: use of frequency distribution curves, scattergrams and regression analyses to compare in vitro activites and describe cross - resistance. Antimicrob Agents Chemother 1993;37:2080-86.
  17. Bryskier A, Bergogne-Berezin E. Macrolides. In: Antibacterial and antifungal agents. Bryskier A, editor. ASM-Press (Washington DC), 2005.
  18. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001;18(Suppl. 1):S71-76.
  19. Li RS, Lee SW, Kong СН. Correlation between bactericidal activity and postantibiotic effect for five antibiotic with different mechanisms of action. J Antimicrob Chemother 1997;40:39-45.
  20. Fang GD, Stout JE, Yu VL. Comparison of intracellular postantibiotic effect of azithromycin and clarithromycin vs. erythromycin against Legionella pneumophila serogroup 1. In: The 36th International Conference on Antimicrobial Agents and Chemotherapy, New Orleans 1996;abstr. A 91.
  21. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 2002;360:978-84.
  22. TreadwayG, PontaniD. ReismanA. The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections. Int J Antimicrob Agents 2002;19:189-94.
  23. Карпов О.И., Зайцев А.Л. Риск применения лекарственных препаратов при беременности и лактации. СПб., 2003. 452 с.
  24. Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 1996;37(suppl. C):143-49.
  25. Rapp RR Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: Enhanced tissue activity and minimal drug interactions. Ann Pharmacother 1998;32(7-8):785-93.
  26. Синопальников А.И., Зайцев А.А. Комплаентность пациентов с инфекциями дыхательных путей // Клиническая микробиология и антимикробная химиотерапия. 2008. № 10(1). С. 50-58.
  27. Белоусов Ю.Б., Шмат С.С., Селевина Т.Г. и др. Фармакоэкономика лечения инфекций нижних дыхательных путей в амбулаторных условиях // Пульмонология. 2000. № 3.
  28. Смоленое И.В., Красильникова А.В. Фармакоэкономические аспекты применения азитромицина различных производителей при внебольничной пневмонии у взрослых // Фарматека. 2003. № 13. С. 78-87.
  29. Карпов О.И. Клинические и фармакоэкономические аспекты применения азитромицина (сумамеда) при инфекциях дыхательных путей // Клиническая фармакология и терапия. 1997. № 4. С. 30-35.
  30. Карпов О.И. Оригинальные препараты и копии макролидов: тенденция противостояния // Фарматека. 2004. № 3/4. С. 34-38.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies